Abstract
Patients with atypical hemolytic uremic syndrome (aHUS) may require ongoing treatment of varying duration. The C5 complement inhibitor eculizumab provides transformative benefits in aHUS; however, knowledge gaps remain regarding treatment patterns/preferences. To address this, we sought to characterize real-world eculizumab use, disease triggers, dialysis and plasma exchange/infusion (PE/PI) in patients with aHUS using US claims data.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
